JP2011528371A5 - - Google Patents

Download PDF

Info

Publication number
JP2011528371A5
JP2011528371A5 JP2011518897A JP2011518897A JP2011528371A5 JP 2011528371 A5 JP2011528371 A5 JP 2011528371A5 JP 2011518897 A JP2011518897 A JP 2011518897A JP 2011518897 A JP2011518897 A JP 2011518897A JP 2011528371 A5 JP2011528371 A5 JP 2011528371A5
Authority
JP
Japan
Prior art keywords
composition
item
immunogenic
particle
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011518897A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011528371A (ja
JP5781929B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/050764 external-priority patent/WO2010009277A2/en
Publication of JP2011528371A publication Critical patent/JP2011528371A/ja
Publication of JP2011528371A5 publication Critical patent/JP2011528371A5/ja
Application granted granted Critical
Publication of JP5781929B2 publication Critical patent/JP5781929B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011518897A 2008-07-15 2009-07-15 免疫原性の両親媒性ペプチド組成物 Expired - Fee Related JP5781929B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8094208P 2008-07-15 2008-07-15
US61/080,942 2008-07-15
PCT/US2009/050764 WO2010009277A2 (en) 2008-07-15 2009-07-15 Immunogenic amphipathic peptide compositions

Publications (3)

Publication Number Publication Date
JP2011528371A JP2011528371A (ja) 2011-11-17
JP2011528371A5 true JP2011528371A5 (cg-RX-API-DMAC7.html) 2012-08-30
JP5781929B2 JP5781929B2 (ja) 2015-09-24

Family

ID=41478598

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011518897A Expired - Fee Related JP5781929B2 (ja) 2008-07-15 2009-07-15 免疫原性の両親媒性ペプチド組成物

Country Status (5)

Country Link
US (1) US20110250237A1 (cg-RX-API-DMAC7.html)
EP (1) EP2313085A2 (cg-RX-API-DMAC7.html)
JP (1) JP5781929B2 (cg-RX-API-DMAC7.html)
CA (1) CA2730737A1 (cg-RX-API-DMAC7.html)
WO (1) WO2010009277A2 (cg-RX-API-DMAC7.html)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7082569B2 (en) 2001-01-17 2006-07-25 Outlooksoft Corporation Systems and methods providing dynamic spreadsheet functionality
US20100015171A1 (en) * 2008-07-15 2010-01-21 Statens Serum Institute Vaccines comprising tb 10.4
CA2765112A1 (en) 2009-06-10 2010-12-16 Novartis Ag Benzonaphthyridine-containing vaccines
EP4183412B1 (en) * 2009-07-15 2024-08-14 GlaxoSmithKline Biologicals SA Rsv f protein compositions and methods for making same
US9597326B2 (en) 2010-04-13 2017-03-21 Glaxosmithkline Biologicals Sa Benzonapthyridine compositions and uses thereof
CA2804591C (en) 2010-07-06 2019-01-22 Novartis Ag Cationic oil-in-water emulsions
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2857499A1 (en) 2010-10-01 2015-04-08 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9327021B2 (en) * 2010-11-15 2016-05-03 Sanofi Pasteur Limited Immunogenic compositions
WO2012089231A1 (en) 2010-12-30 2012-07-05 Okairòs Ag Paramyxovirus vaccines
US10357568B2 (en) 2011-03-24 2019-07-23 Glaxosmithkline Biologicals S.A. Adjuvant nanoemulsions with phospholipids
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
RS56748B1 (sr) 2011-05-13 2018-03-30 Glaxosmithkline Biologicals Sa Pre-fuzioni rsv f antigeni
KR20220025112A (ko) 2011-06-08 2022-03-03 샤이어 휴먼 지네틱 테라피즈 인크. Mrna 전달을 위한 지질 나노입자 조성물 및 방법
US9655845B2 (en) 2011-07-06 2017-05-23 Glaxosmithkline Biologicals, S.A. Oil-in-water emulsions that contain nucleic acids
US9636410B2 (en) 2011-07-06 2017-05-02 Glaxosmithkline Biologicals Sa Cationic oil-in-water emulsions
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
PT3682905T (pt) 2011-10-03 2022-04-07 Modernatx Inc Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações
ES2923757T3 (es) 2011-12-16 2022-09-30 Modernatx Inc Composiciones de ARNm modificado
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
CN104736563A (zh) 2012-07-27 2015-06-24 国家健康与医学研究院 Cd147作为受体用于脑膜炎球菌至血管内皮的菌毛介导的粘附
US9512456B2 (en) 2012-08-14 2016-12-06 Modernatx, Inc. Enzymes and polymerases for the synthesis of RNA
EP2885010B1 (en) 2012-08-16 2020-01-01 Ipierian, Inc. Methods of treating a tauopathy
KR20150085843A (ko) 2012-11-20 2015-07-24 글락소스미스클라인 바이오로지칼즈 에스.에이. Rsv f 융합전 삼합체
US20140141037A1 (en) * 2012-11-20 2014-05-22 Novartis Ag Rsv f prefusion trimers
PT2922554T (pt) 2012-11-26 2022-06-28 Modernatx Inc Arn modificado nas porções terminais
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
US20160024181A1 (en) 2013-03-13 2016-01-28 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
US10258698B2 (en) 2013-03-14 2019-04-16 Modernatx, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
AU2014228765A1 (en) * 2013-03-15 2015-10-15 Medimmune, Llc Palivizumab epitope-based virus-like particles
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
CN105939722A (zh) 2014-02-14 2016-09-14 伊皮埃里安股份有限公司 Tau肽，抗Tau抗体，及其使用方法
HRP20220070T1 (hr) 2014-04-23 2022-04-01 Modernatx, Inc. Cjepiva nukleinske kiseline
EP2974739A1 (en) 2014-07-15 2016-01-20 Novartis AG RSVF trimerization domains
EP3154576A1 (en) 2014-06-13 2017-04-19 GlaxoSmithKline Biologicals S.A. Immunogenic combinations
WO2016011226A1 (en) 2014-07-16 2016-01-21 Moderna Therapeutics, Inc. Chimeric polynucleotides
TWI781904B (zh) 2014-10-03 2022-11-01 澳大利亞商恩吉尼克分子傳遞私人有限公司 使細菌衍生之完整囊泡對小分子化合物增強裝載之技術
EP3031822A1 (en) * 2014-12-08 2016-06-15 Novartis AG Cytomegalovirus antigens
CN107106668A (zh) * 2014-12-10 2017-08-29 华西亚生医有限公司 用于免疫中的有效抗体生产的新颖蛋白质结构
AU2016238290B9 (en) 2015-03-25 2019-06-13 The Regents Of The University Of Michigan Compositions and methods for delivery of biomacromolecule agents
EP3359670B2 (en) 2015-10-05 2024-02-14 ModernaTX, Inc. Methods for therapeutic administration of messenger ribonucleic acid drugs
EP3471778A4 (en) 2016-06-20 2020-02-19 The Regents of The University of Michigan COMPOSITIONS AND METHOD FOR DELIVERING BIOMACROMOLECOLIC ACTIVE SUBSTANCES
JP7467458B2 (ja) * 2018-07-30 2024-04-15 中央研究院 コアセルベート複合化による治療用ナノ粒子および細菌を処理するためのそれらの使用
KR102184153B1 (ko) * 2019-02-25 2020-11-30 부산대학교 산학협력단 고분자 지지체 기반의 인플루엔자 바이러스 유사 구조체 및 이의 제조방법
EP3942056A4 (en) 2019-03-22 2022-12-21 Kansas State University Research Foundation LIPID INCLUDED AMPHIPATHIC PEPTIDES
MX2022002980A (es) 2019-09-16 2022-04-06 Amgen Inc Metodo para la esterilizacion externa de un dispositivo de suministro de farmacos.
KR20230097028A (ko) * 2020-10-28 2023-06-30 사노피 파스퇴르 Tlr4 효현제를 함유하는 리포좀, 이의 제조 및 용도
WO2022103927A1 (en) * 2020-11-12 2022-05-19 Shape Biopharmaceuticals Inc. Immunogenic compositions for coronaviruses
US20240279313A1 (en) * 2021-08-11 2024-08-22 The Regents Of The University Of California Barrier function preserving peptides for membranes
WO2025242657A1 (en) 2024-05-21 2025-11-27 Shape Biopharmaceuticals Ag Lipopeptide building blocks and aggregates

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0749376B2 (ja) * 1988-12-16 1995-05-31 アルバニー メディカル カレジ 免疫原性組成物および医薬組成物
WO1997038010A2 (en) * 1996-04-11 1997-10-16 The University Of British Columbia Fusogenic liposomes
US7208314B2 (en) * 2002-02-26 2007-04-24 Mirus Bio Corporation Compositions and methods for drug delivery using pH sensitive molecules
WO2004073684A2 (en) * 2003-02-14 2004-09-02 Children's Hospital & Research Center At Oakland Lipophilic drug delivery vehicle and methods of use thereof
EP1677763A1 (en) * 2003-10-01 2006-07-12 Children's Hospital & Research Center at Oakland Lipophilic drug delivery vehicle and methods of use thereof
US8252338B2 (en) * 2005-11-10 2012-08-28 The Regents Of The University Of California Synthetic LDL as targeted drug delivery vehicle

Similar Documents

Publication Publication Date Title
JP4294584B2 (ja) 核酸ワクチン接種の免疫応答を高めるための方法
DK2729127T3 (en) METHODS FOR LIPOSOMES PREPARATION
US20170307612A1 (en) Kit for detecting virus
Atmar et al. Adjuvants for pandemic influenza vaccines
JP5775451B2 (ja) インフルエンザを処置するための組成物および方法
Carmona-Ribeiro et al. Cationic nanostructures for vaccines design
TW201427686A (zh) 改良之疫苗組成物及使用方法
JP2013526617A5 (cg-RX-API-DMAC7.html)
MX2011002267A (es) Vacuna.
CN102905726A (zh) 包含抗原和Toll样受体激动剂的口服疫苗
JP7409594B2 (ja) 医薬組成物、規定のサイズの脂質ベシクル粒子を使用する調製物のための方法、及びそれらの使用
JP2010535026A (ja) 多量体マルチエピトープインフルエンザワクチン
WO2007132790A1 (ja) 細菌菌体成分を含む脂質膜を有するリポソーム
JP2013533259A (ja) インフルエンザを治療するための組成物及び方法
CN111565706A (zh) 药物组合物、包括脂质囊泡颗粒尺寸设定的制备方法及其用途
CN103002908B (zh) 粘膜疫苗
Jalilian et al. Properties and prospects of adjuvants in influenza vaccination-messy precipitates or blessed opportunities?
US20240366747A1 (en) Universal vaccine for influenza virus based on tetrameric m2 protein incorporated into nanodiscs
JPH08506592A (ja) ３−ｏ−脱アシル化モノホスホリル脂質Ａ含有のインフルエンザワクチン組成物
Karpe et al. Virosome: A vector in vaccine delivery
US10426828B2 (en) Compositions of multimeric-multiepitope influenza polypeptides and their production
TW201217000A (en) Vaccine compositions based on sticholysin encapsulated into liposomes
Mendoza‐Ramírez et al. Silica nanoparticles as multifunctional platforms for vaccine delivery and immune modulation in infectious diseases
US12006350B2 (en) Triblock peptide amphiphiles, micelles and methods of use
CN103282049B (zh) 免疫原性组合物